Skip to content
Menu

Protara Therapeutics, Inc. TARA

Full chart Compare
Set alert

Price alert · TARA

All alert types
2.28 USD -0.12 (-5.00%)

Regular-session close

2.28 0.00 0.00%

After hours · Nov 20, 4:01 PM ET

2.25 Day range 2.42
2.09 52-week range 7.82
YTD
-57.22%
1 year
-64.60%

Discussion (63)

Zeev Bovan TARA 1 week ago #1

It will blast off eventually, down 50% on this and still laughing, mybe will buy more. $TARA

Zeev Bovan TARA 1 week ago #2

$TARA Oppenheimer Maintains Outperform on Protara Therapeutics, Raises Price Target to $28.

The risk reward here make it a phenomenal stock to buy and hold/accumulate.

Zeev Bovan TARA 1 month ago #3

Things are moving in the right direction, when this stock is traded at 26-30$ who will care that it was dirt cheap today. $TARA

Zeev Bovan TARA 1 month ago #4

$TARA Protara Therapeutics Completes Enrollment of the Phase 2b Open-Label Dose Confirmation Phase of the THRIVE-3 Registrational Trial of IV Choline Chloride in Patients on Parenteral Support
Protara Therapeutics
October 15, 2026 08:00 ET

Little shaking and they be running lol

Zeev Bovan TARA 1 month ago #5

$TARA those who are afraid to lose don’t deserve win. Once they get FDA approval they will reach analyst target price and it will just be the beginning of something bigger.

Zeev Bovan TARA 1 month ago #6

I am on board till the end whether it goes to 0 or I will become a hero. As per the test results things are fine, Bank of America loaded up on $TARA, something is happening, could be happening, shorts closing thier positions or a dump before a huge pump/news.

Zeev Bovan TARA 1 month ago #7
  1. THRIVE-3 Trial Interim Results (Estimated Window: November – December 2026)
    • The Milestone: This is the most crucial near-term "success or failure" binary event. The registrational Phase 3 trial is testing IV Choline Chloride for patients dependent on long-term intravenous nutrition.
    • What Success Looks Like: Positive interim data from this study will mathematically validate the drug's efficacy and safety profiles, directly smoothing the path toward regulatory approval.
  2. STARBORN-1 Pivotal Trial Update (Estimated Window: November – December 2026)
    • The Milestone: Full enrollment completion and a comprehensive data update from the STARBORN-1 trial evaluating their lead asset, TARA-002, in pediatric lymphatic malformations.
    • What Success Looks Like: Strong efficacy and durability metrics here are critical because the company is actively preparing this exact dataset to support their Biologics License Application (BLA) submission to the FDA
Zeev Bovan TARA 1 month ago #8

Idiots, put stop loss on future profits, wait till December, that’s when things should start moving.

Zeev Bovan TARA 1 month ago #9

When it skyrockets institutions/smart money will love it at 20-26$. $TARA our time will come.

Zeev Bovan TARA 1 month ago #10

$TARA it’s coming eventually, so many analysts can’t be wrong, just a question of time, when it becomes really parabolical it’s going to be beautiful to watch.

Sign in to join the discussion